Latest treatment strategies for membranous nephropathy

Bibliography

• CAMERON JS: Membranous nephropathy and its treatment. Nephrol. Dial. Transplant. (1992) 7:S72-S79.
   PubMed Web of Science ®Google Scholar
• RONCO P, DEBIEC H: Molecular pathomechanisms of membranous nephropathy: from Heymann nephritis to alloimmunization. J. Am. Soc. Nephrol. (2005) 16:1205-1213.
   PubMed Web of Science ®Google Scholar
• NANGAKU M, SHANKLAND SJ, COUSER WG: Cellular response to injury in membranous nephropathy. J. Am. Soc. Nephrol. (2005) 16(5):1195-1204.
   PubMed Web of Science ®Google Scholar
• SCHIEPPATI S, MOSCONI L, PERNA A et al.: Prognosis of untreated patients with idiopathic membranous nephropathy. N. Engl. J. Med. (1993) 329:85-89.
   PubMed Web of Science ®Google Scholar
• HONKANEN E, TORNROTH T, GROHAGEN-RISKA C: Natural history, clinical course and morphological evolution of membranous nephropathy. Nephrol. Dial. Transplant. (1992) 7:S35-S41.
   PubMed Web of Science ®Google Scholar
• GLASSOCK RJ: The therapy of idiopathic membranous glomerulonephritis. Semin. Nephrol. (1991) 11:138-147.
   PubMed Web of Science ®Google Scholar
• CATTRAN D: Management of membranous nephropathy: when and what for treatment. J. Am. Soc. Nephrol. (2005) 16:1188-1194.
   PubMed Web of Science ®Google Scholar
• PERNA A, SCHIEPPATI A, ZAMORA J et al.: Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am. J. Kidney Dis. (2004) 44:385-401.
   PubMed Web of Science ®Google Scholar
• CATTRAN DC, DELMORE T, ROSCOE J et al.: A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N. Engl. J. Med. (1989) 26:210-215.
   Google Scholar
• HOGAN SL, MULLER KE, JENNETTE JC, FALK RJ: A review of therapeutic studies of idiopathic membranous nephropathy. Am. J. Kidney Dis. (1995) 25: 862-875.
   PubMed Web of Science ®Google Scholar
• IMPERIALE TF, GOLDFARB S, BERNS JS: Are cytotoxic agents beneficial in idiopathic membranous nephropathy? A meta-analysis of the controlled trials. J. Am. Soc. Nephrol. (1995) 5:1553-1558.
   PubMed Web of Science ®Google Scholar
• PONTICELLI C, ZUCCHELLI P, PASSERINI P et al.: A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int. (1995) 48:1600-1604.
   PubMed Web of Science ®Google Scholar
• JHA V, GANGLI A, SAHA T et al.: A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J. Am. Soc. Nephrol. (2007) 18:1899-1904.
   PubMed Web of Science ®Google Scholar
• CHOI MJ, EUSTACE JA, GIMENEZ LF et al.: Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int. (2002) 61:1068-1114.
   Google Scholar
• BERG AL, NILSSON-EHLE P, ARNADOTTIR M: Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. Kidney Int. (1999) 56:1534-1543.
   PubMed Web of Science ®Google Scholar
• REMUZZI G, CHIURCHIU C, ABBATE M, BRUSEGAN V, BONTEMPELLI M, RUGGENENTI P: Rituximab for idiopathic membranous nephropathy. Lancet (2002) 360:923-924.
   PubMed Web of Science ®Google Scholar
• DURIN S, BARBANEL C, LANDAIS P et al.: Long term course of idiopathic extramembranous glomerulonephritis. Study of predictive factors of terminal renal insufficiency in 82 untreated patients. Nephrologie (1990) 11:67-71.
   PubMedGoogle Scholar
• DONADIO JJV, TORRES VE, VELOSA JA et al.: Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int. (1988) 33:708-715.
   PubMed Web of Science ®Google Scholar
• HONKANEN E, TORNROTH T, GRONHAGEN-RISKA C et al.: Long-term survival in idiopathic membranous glomerulonephritis: can the course be clinically predicted? Clin. Nephrol. (1994) 41:127-134.
   PubMedGoogle Scholar
• PEI Y, CATTRAN DC, GREENWOOD C: Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int. (1992) 42:960-966.
   PubMed Web of Science ®Google Scholar
• REICHERT LJM, KOENE RAP, WETZELS JFM: Prognostic factors in idiopathic membranous nephropathy. Am. J. Kidney Dis. (1998) 31:1-11.
   PubMed Web of Science ®Google Scholar
• BAZZI C, PETRINI C, RIZZA V et al.: Urinary excretion of IgG and α1-microglobulin predicts clinical course better than extent of proteinuria in membranous nephropathy. Am. J. Kidney Dis. (2001) 38:240-248.
   PubMed Web of Science ®Google Scholar
• REICHERT LJM, KOENE RAP, WETZELS JFM: Urinary excretion of β2-microglobulin predicts renal outcome in patients with idiopathic membranous nephropathy. J. Am. Soc. Nephrol. (1995) 6:1666-1669.
   PubMed Web of Science ®Google Scholar
• BRENCHLEY PE, COUPES B, SHORT CD et al.: Urinary C3dg and C5b-9 indicate active immune disease in human membranous nephropathy. Kidney Int. (1992) 41:933-937.
   PubMedGoogle Scholar
• DU BUF-VEREIJKEN PW, BRANTEN AJ, WETZELS JF: Idiopathic membranous nephropathy: outline and rationale of a treatment strategy. Am. J. Kidney Dis. (2005) 46:1012-1029.
   PubMedGoogle Scholar
• CYBULSKY A, QUIGG RJ, SALANT DJ: Experimental membranous nephropathy redux. Am. J. Physiol. Renal Physiol. (2005) 289:F660-F671.
   PubMed Web of Science ®Google Scholar
• KERJASCHKI D, FARQUHAR MG: Immunocytochemical localization of the Heymann nephritis antigen (gp330) in glomerular epithelial cells of normal Lewis rats. J. Exp. Med. (1983) 157:667-686.
   PubMed Web of Science ®Google Scholar
• CUNNINGAM PN, QUIGG RJ: Contrasting roles of complement activation and its regulation in membranous nephropathy. J. Am. Soc. Nephrol. (2005) 16:1214-1222.
   PubMedGoogle Scholar
• LEENAERTS PL, HALL BM, VAN DAMME BJ et al.: Active Heymann nephritis in complement C6 deficient rats. Kidney Int. (1995) 47:1604-1614.
   PubMedGoogle Scholar
• BAKER PJ, OCHI RF, SCHULZE M, JOHNSON RJ, CAMPBELL C, COUSER WG: Depletion of C6 prevents development of proteinuria in experimental membranous nephropathy in rats. Am. J. Pathol. (1989) 135:185-194.
   PubMed Web of Science ®Google Scholar
• SCHULZE M, BAKER PJ, PERKINSON DT et al.: Increased urinary excretion of C5b-9 distinguishes passive Heymann nephritis in the rat. Kidney Int. (1989) 35:60-68.
   PubMedGoogle Scholar
• BRANTEN AJ, KOCK-JANSEN M, KLASEN IS, Wetzels JF: Urinary excretion of complement C3d in patients with renal diseases. Eur. J. Clin. Invest. (2003) 33:449-456.
   PubMedGoogle Scholar
• LEHTO T, HONKANEN E, TEPPO AM, MERI S: Urinary excretion of protectin (CD59), complement SC5b-9 and cytokines in membranous glomerulonephritis. Kidney Int. (1995) 47:1403-1411.
   PubMedGoogle Scholar
• DEBIEC H, GUIGONIS V, MOUGENOT M et al.: Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N. Eng. J. Med. (2002) 346:2053-2060.
   PubMed Web of Science ®Google Scholar
• RONCO P, ALLEGRI L, BRIANTI E et al.: Antigenic targets in epimembranous glomerulonephritis. Experimental data and potential application in human pathology. Appl. Pathol. (1989) 7:85-89.
   PubMedGoogle Scholar
• ASSMANN KJ, VAN SON JP, DIJKMAN HB, KOENE RA: A nephritogenic rat monoclonal antibody to mouse aminopeptidase A. Induction of massive albuminuria after a single intravenous injection. J. Exp. Med. (1992) 175:623-635.
   PubMedGoogle Scholar
• COLLABORATIVE STUDY OF THE ADULT IDIOPATHIC NEPHROTIC SYNDROME: A controlled study of short-term prednisone treatment in adults with membranous nephropathy. N. Engl. J. Med. (1979) 13:1301-1306.
   Google Scholar
• CAMERON JS, HEALY MJ, ADU D: The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC glomerulonephritis working party. Q. J. Med. (1990) 74:133-156.
   PubMedGoogle Scholar
• PONTICELLI C, ZUCCHELLI P, IMBASCIATI E et al.: Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N. Eng. J. Med. (1984) 310:946-950.
   PubMed Web of Science ®Google Scholar
• PONTICELLI C, ALTIERI P, SCOLARI F et al.: A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. (1998) 9:444-450.
   PubMed Web of Science ®Google Scholar
• BRAUN N, ERLEY C, BENDA N et al.: Therapy of membranous glomerulonephritis with nephrotic syndrome. 5 years follow-up of a prospective, randomized multi-center study. Nephrol. Dial. Transplant. (1995) 10:A967.
   Google Scholar
• CATTRAN DC, APPEL GB, HEBERT LA et al.: Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int. (2001) 59:1484-1490.
   PubMed Web of Science ®Google Scholar
• ALEXOPOULOS E, PAPAGIANNI A, TSAMELASHVILI M et al.: Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrol. Dial. Transplant. (2006) 21:3127-3132.
   PubMed Web of Science ®Google Scholar
• PRAGA M, BARRIO V, JUAREZ GF, LUNO J: Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. (2007) 71:924-930.
   PubMed Web of Science ®Google Scholar
• SALAMA AD, PUSEY CD: Drug insight: rituximab in renal disease and transplantation. Nat. Clin. Pract. Nephrol. (2006) 2:221-230.
   PubMedGoogle Scholar
• KAPLAN M: Eculizumab (Alexion). Curr. Opin. Investig. Drugs (2002) 3:1017-1023.
   PubMedGoogle Scholar
• APPEL G, NACHMAN P, HOGAN S et al.: Eculizumab (C5 complement inhibitor) in the treatment of idiopathic membranous nephropathy. J. Am. Soc. Nephrol. (2002) 13:A668.
   PubMed Web of Science ®Google Scholar
• COHEN CD, CALVARESI N, ARMELLONI S et al.: CD20-positive infiltrates in human membranous glomerulonephritis. J. Nephrol. (2005) 18:328-333.
   PubMed Web of Science ®Google Scholar
• RUGGENENTI P, CHIURCHIU C, BRUSEGAN V et al.: Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J. Am. Soc. Nephrol. (2003) 14:1851-1857.
   PubMed Web of Science ®Google Scholar
• FERVENZA FC, HERZENBERG AM, ERICKSON SB et al.: Variation in response to rituximab in the treatment of idiopathic membranous nephropathy: preliminary results at 1 year. J. Am. Soc. Nephrol. (2006) 14:A570.
   Google Scholar
• COBO M, HERNANDEZ D, RODRIGUEZ C, PEREZ-TAMAJON L: Successful therapeutic use of rituximab in refractory membranous glomerulonephritis. Clin. Nephrol. (2006) 66:54-57 (Abstract).
   PubMedGoogle Scholar
• GALLON L, CHHABRA D: Anti-CD20 monoclonal antibody (rituximab) for the treatment of recurrent idiopathic membranous nephropathy in a renal transplant patient. Am. J. Transplant. (2006) 6:3017-3021.
   PubMed Web of Science ®Google Scholar
• RUGGENENTI P, CHIURCHIU C, ABBATE M et al.: Rituximab for idiopathic membranous nephropathy: who can benefit? Clin. J. Am. Soc. Nephrol. (2006) 1:738-748.
   PubMed Web of Science ®Google Scholar
• CAMBRIDGE G, LEANDRO MJ, EDWARDS JCW et al.: Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. (2003) 48: 2146-2154.
   PubMed Web of Science ®Google Scholar
• MAKKER SP, KANALAS JJ: Course of transplanted Heymann nephritis kidney in normal host. Implications for mechanism of proteinuria in membranous glomerulonephropathy. J. Immunol. (1989) 142:3406-3410.
   PubMedGoogle Scholar
• SHEMESH O, ROSS JC, DEEN WM et al.: Nature of the glomerular capillary injury in human membranous glomerulopathy. J. Clin. Invest. (1986) 77:868-877.
   PubMedGoogle Scholar
• SHIPKOVA M, ARMSTRONG VW, OELLERICH M, WIELAND E: Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. Expert Opin. Drug Metab. Toxicol. (2005) 1:505-526.
   PubMedGoogle Scholar
• MILLER G, ZIMMERMAN R III, RADHAKRISHNAN J, APPEL G: Use of mycophenolate mofetil in resistant membranous nephropathy. Am. J. Kidney Dis. (2000) 36:250-256.
   PubMed Web of Science ®Google Scholar
• PONTICELLI C, PASSERINI P, SALVADORI M et al.: A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopatic membranous nephropathy. Am. J. Kidney Dis. (2006) 47:233-240.
   PubMed Web of Science ®Google Scholar
• BERG AL, NILSSON-EHLE P: Direct effects of corticotropin on plasma lipoprotein metabolism in man-studies in vivo and in vitro. Metabolism (1994) 431:90-97.
   PubMedGoogle Scholar
• GHIGGERI GM, BRUSCHI M, CANDIANO G et al.: Depletion of clusterin in renal diseases causing nephrotic syndrome. Kidney Int. (2002) 62:2184-2194.
   PubMedGoogle Scholar
• ORLANDO RA, KERJASHI D, FARQUHAR MG: Megalin (gp330) possesses an antigenic epitope capable of inducing passive Heymann nephritis independent of the nephritogenic epitope in receptor-associated protein. J. Am. Soc. Nephrol. (1995) 6:61-65.
   PubMedGoogle Scholar
• REMUZZI G, BENIGNI A, REMUZZI A: Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J. Clin. Invest. (2006) 116:288-296.
   PubMed Web of Science ®Google Scholar
• LEWIS EJ, HUNSICKER LG, BAIN RP, ROHDE RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group. N. Engl. J. Med. (1993) 329:1456-1462.
   PubMed Web of Science ®Google Scholar
• BRENNER BM, COOPER ME, DE ZEEUW D et al.; RENAAL STUDY INVESTIGATORS: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. (2001) 345:861-869.
   PubMed Web of Science ®Google Scholar
• THE GISEN GROUP: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet (1997) 349:1857-1863.
   PubMedGoogle Scholar
• ZOJA C, CORNA D, CAMOZZI D et al.: How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J. Am. Soc. Nephrol. (2002) 13:2898-2908.
   PubMed Web of Science ®Google Scholar
• REMUZZI G, RUGGENENTI P: Overview of randomised trials of ACE inhibitors. Lancet (2006) 368:555-556.
   PubMed Web of Science ®Google Scholar
• MACCONI D, ABBATE M et al.: Permselective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention. Am. J. Pathol. (2006) 168:1073.
   PubMed Web of Science ®Google Scholar
• BENIGNI A, TOMASONI S, GAGLIARDINI E et al.: Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis. J. Am. Soc. Nephrol. (2001) 12:941-948.
   PubMed Web of Science ®Google Scholar
• RUGGENENTI P, MOSCONI L, VENDRAMIN G et al.: ACE inhibition improves glomerular size selectivity in patients with idiopatic membranous nephropathy and persistent nephrotic syndrome. Am. J. Kidney Dis. (2000) 35:381-391.
   PubMed Web of Science ®Google Scholar
• SCHIEPPATI A, RUGGENENTI P, PERNA A, REMUZZI G: Nonimmunosuppressive therapy of membranous nephropathy. Sem. Nephrol. (2003) 23:333-339.
   PubMed Web of Science ®Google Scholar
• THOMAS DM, HILLIS AN, COLES GA et al.: Enalapril can treat proteinuria of membranous glomerulonephritis without detriment to systemic or renal hemodynamics. Am. J. Kidney Dis. (1991) 18:38-43.
   PubMed Web of Science ®Google Scholar
• RUGGENENTI P, PERNA A, REMUZZI G (FOR THE GISEN GROUP): Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int. (2003) 63:2254-2261.
   PubMed Web of Science ®Google Scholar
• RUGGENENTI P, SCHIEPPATI A, REMUZZI G: Progression, remission, regression of chronic renal diseases. Lancet (2001) 19:1601-1608.
   Google Scholar
• CAMPBELL R, SANGALLI F, PERTICUCCI E et al.: Effects of combined ACE inhibitor and angiotensin II receptor antagonist treatment in human chronic nephropathies. Kidney Int. (2003) 63:1094-1103.
   PubMed Web of Science ®Google Scholar
• NAKAO N, YOSHIMURA A, MORITA H et al.: Combination treatment of angiotensin II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet (2003) 361:117-124.
   PubMed Web of Science ®Google Scholar
• BUEMI M, NOSTRO L, CRASCI E et al.: Statins in nephrotic syndrome: a new weapon against tissue injury. Med. Res. Rev. (2005) 25: 587-609.
   PubMed Web of Science ®Google Scholar
• HIPPOCRATES: Corpus hippocraticum, 460-370 BC.
   Google Scholar
• DONADIO JV Jr, HOLLEY KE, ANDERSON CF, TAYLOR WF: Controlled trial of cyclophosphamide in idiopathic membranous nephropathy. Kidney Int. (1974) 6:431-439.
   PubMed Web of Science ®Google Scholar
• MURPHY BF, MCDONALD I, FAIRLEY KF, KINCID-SMITH PS: Randomised controlled trial of cyclophosphamide, warfarin and dipyridamole in idiopathic membranous glomerulonephritis. Clin. Nephrol. (1992) 37:229-234.
   PubMed Web of Science ®Google Scholar
• PONTICELLI C, ZUCCHELLI P, PASSERINI P et al.: A randomised trial of methyprednisolone and chlorambucil in idiopathic membranous nephropathy. N. Eng. J. Med. (1989) 320:8-13.
   PubMed Web of Science ®Google Scholar